Cancer-associated thrombosis in Asia

被引：19

作者：

Angchaisuksiri P. ^{[1
]}

机构：

[1] Mahidol University, Division of Hematology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, 270 RAMA VI Road., Rachathevi, Bangkok

来源：

Thrombosis Journal | / 14卷 / Suppl 1期

关键词：

Asian; Cancer; Thrombosis;

D O I：

10.1186/s12959-016-0110-4

中图分类号：

学科分类号：

摘要：

Thrombosis is a common complication in cancer patients. Although the major inherited risk factors for thrombophilia are different between Asians and Caucasians, the main acquired risk factors that are associated with the development of venous thromboembolism (VTE) in Asians appear to be similar to those for Caucasians. Malignancy is the most important acquired risk factor for VTE in Asians. Recent studies have shown that the incidence of VTE is significant in Asian patients with cancer, particularly those in an advanced stage. Cancer associated VTE is more severe and associated with higher morbidity and mortality. Unprovoked VTE is associated with an increased risk of subsequent cancer diagnosis. A number of international and national guidelines are available to provide guidance to healthcare providers to treat and prevent this serious complication based on best-available evidence. Identifying cancer patients at risk for VTE and use of appropriate thromboprophylaxis in these patients can potentially improve morbidity and mortality. Although direct oral anticoagulants (DOACs) may become an attractive treatment for cancer-associated VTE, further clinical trials are needed to evaluate the safety and efficacy of DOACs directly against LMWH in cancer patients. © 2016 The Author(s).

引用

共 32 条

[21]

Agnelli G., Buller H.R., Cohen A., Gallus A.S., Lee T.C., Pak R., Et al., Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial, J Thromb Haemost, 13, pp. 2187-2191, (2015)

[22]

Raskob G.E., van Es N., Segers A., Angchaisuksiri P., Oh D., Boda Z., Et al., Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial, Lancet Haematol., 3, 8, (2016)

[23]

Schulman S., Goldhaber S.Z., Kearon C., Kakkar A.K., Schellong S., Eriksson H., Et al., Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer, Thromb Haemost, 114, pp. 150-157, (2015)

[24]

Vedivati M.C., Germini F., Agnelli G., Becattini C., Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest, 147, pp. 475-483, (2015)

[25]

Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., Et al., Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, pp. 2499-2510, (2010)

[26]

Buller H.R., Prins M.H., Lensing A.W., Decousus H., Jacobson B.F., Minar E., Et al., Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, pp. 1287-1297, (2012)

[27]

Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Et al., Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, pp. 799-808, (2013)

[28]

Buller H.R., Decousus H., Grosso M.A., Mercuri M., Middledorp S., Prins M.H., Et al., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, pp. 1406-1415, (2013)

[29]

Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., Et al., Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, pp. 2342-2352, (2009)

[30]

Schulman S., Kakkar A.K., Goldhaber S.Z., Schellong S., Eriksson H., Mismetti P., Et al., Treatment of venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, pp. 764-772, (2014)

← 1 2 3 4 →